Physician profile
Albert A Herrera
NPI 1497717250
$4,057.08
in general payments reported to CMS, 2019-2025
38 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $580 · 2021: $546 · 2022: $318 · 2023: $307 · 2024: $847 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $895.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $488.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $417.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $298.71 | 2021-2025 | |
| Pfizer INC. | $213.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.40 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.56 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $146.22 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $125.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.08 | 2019-2024 | Airsupra |
| Sunovion Pharmaceuticals INC. | $115.43 | 2019-2022 | |
| Astellas Pharma US INC | $92.16 | 2019-2024 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $85.19 | 2019-2021 | |
| Esperion Therapeutics, INC. | $76.74 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $66.21 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.